SCHEMBL5875892

SCHEMBL5875892

CCSc1cnc(C(N)=O)s1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.39
CCNE1 P24864 14/20 0.38
CDK2 P24941 14/20 0.38
CCNE2 O96020 13/20 0.38
CDK4 P11802 6/20 0.38
CDK1 P06493 5/20 0.38
CCND1 P24385 5/20 0.38
CCNB2 O95067 4/20 0.38
CCNB1 P14635 4/20 0.38
CCNB3 Q8WWL7 4/20 0.38
EPHX2 P34913 1/20 0.35
NPC1 O15118 1/20 0.34
POLB P06746 1/20 0.34
RAB9A P51151 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
PIK3CD O00329 1/20 0.34
PIK3CA P42336 1/20 0.34
PIK3CB P42338 1/20 0.34
PI4KA P42356 1/20 0.34
PIK3CG P48736 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15538021 0.79 CCNE1 (0.41) CCNE1CDK2TSHR
SCHEMBL6691889 0.74 CDK2 (0.47) CCNE1CDK2CCNE2CDK4CDK1
SCHEMBL5875895 0.73
SCHEMBL14714709 0.73 CDK2 (0.68) CCNE1CDK2CCNE2CDK4CDK1
SCHEMBL3340646 0.72 MEN1 (0.40) NPC1RAB9ATSHR
SCHEMBL2827606 0.72 SMYD3 (0.47) CCNE1CDK2TSHR
SCHEMBL3904544 0.71 RAB9A (0.45) POLBRAB9A
SCHEMBL16731888 0.71 CCNE1 (0.68) CCNE1CDK2CCNE2CDK4CDK1
SCHEMBL21133103 0.71
SCHEMBL3547268 0.70 NTRK1 (0.37) TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2006504796-A 2006-02-09 JP claimed
EP-1551815-A1 THIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS Pfizer Products Inc. (US) 2005-07-13 EP claimed
US-20040152747-A1 Thiazole compounds for treatment of neurodegenerative disorders PFIZER INC 2004-08-05 US claimed
WO-2004033439-A1 THIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS PFIZER PRODUCTS INC. (US) 2004-04-22 WO claimed
EP-1551815-A1 THIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS Pfizer Products Inc. (US) 2005-07-13 EP disclosed
US-20040152747-A1 Thiazole compounds for treatment of neurodegenerative disorders PFIZER INC 2004-08-05 US disclosed
WO-2004033439-A1 THIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS PFIZER PRODUCTS INC. (US) 2004-04-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152747-A1 Thiazole compounds for treatment of neurodegenerative disorders APP, PARK7, IAPP HSD17B10 2162/4885CCNE1 1853/4885CDK2 1792/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.